Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Research Library

Tesamorelin research

6 articles to explore, with links to 6 original sources.

About Tesamorelin

Tesamorelin is a modified analogue of growth hormone-releasing hormone used in receptor signaling research.

Explore study findings

  • What a randomized extension showed when participants switched to placebo

    Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with an added chemical group at its starting end. An older clinical trial used a second randomized phase to ask what happened to abdominal visceral fat when participants continued the study treatment or switched to placebo.

    2 sources (2010, 2026)

Check methods and identity

  • What the current U.S. label means by excess abdominal fat

    Tesamorelin is a synthetic analogue of human growth hormone–releasing factor. It contains the 44-amino-acid sequence of that hormone and an added chemical group at the beginning. What does the approved indication mean when it describes a reduction in excess abdominal fat?

    2 sources (2010, 2026)

  • What the TRIUMPH trial is designed to measure about physical function

    Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with a chemical modification at its starting end. It can stimulate the pituitary to release growth hormone.

    2 sources (2026)

  • What bioequivalence means in a comparison of tesamorelin formulations

    Tesamorelin is a chemically modified 44-residue analogue of growth hormone–releasing hormone. A report published in January 2026 compared how the newer Egrifta WR formulation and the original Egrifta formulation appeared in the blood of healthy adults.

    2 sources (2026)

  • What a liver-fat trial measured beyond abdominal fat

    Tesamorelin is a chemically modified, 44-residue analogue of growth hormone–releasing hormone that stimulates the pituitary. An older trial asked whether the drug affected fat stored in the liver in adults with HIV and fatty liver disease.

    2 sources (2019, 2026)

Interpret the evidence

  • Why a smaller waist did not establish improved cognition in an HIV trial

    Tesamorelin is a 44-residue analogue of growth hormone–releasing hormone with a chemical group attached at its starting end. An older randomized trial asked whether tesamorelin changed thinking and memory measures in adults with HIV, abdominal obesity and neurocognitive impairment.

    2 sources (2025, 2026)

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice.